I don't really buy what he's saying. Sure there are future liabilities but BGL's current EBITDA run rate is $9m compared to FY11 total result of $5.4m.
Also of note is that their annualised EBITDA run rate's increased from $7.5m to $9m in the space of 4 months. Would it be reasonable to anticipate another $4.5m annualised EBITDA run rate growth by the end of FY12? Depends on the size of their sales pipeline :)
How does everyone feel about the likelyhood of an FY12 dividend seeing as new sites in Canberra and Wollongong look like a done deal?
- Forums
- ASX - By Stock
- BGL
- 2012 guidance
2012 guidance, page-4
Featured News
Add BGL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.33 |
Change
-0.083(5.83%) |
Mkt cap ! $1.708B |
Open | High | Low | Value | Volume |
$1.36 | $1.37 | $1.30 | $7.413M | 5.580M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
30 | 80197 | $1.33 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.34 | 30636 | 19 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
23 | 27312 | 1.330 |
25 | 78133 | 1.325 |
18 | 101966 | 1.320 |
18 | 223432 | 1.315 |
13 | 145974 | 1.310 |
Price($) | Vol. | No. |
---|---|---|
1.335 | 28327 | 17 |
1.340 | 82683 | 14 |
1.345 | 173943 | 14 |
1.350 | 471754 | 20 |
1.355 | 14612 | 3 |
Last trade - 13.40pm 12/11/2024 (20 minute delay) ? |
Featured News
BGL (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online